Given the wide-reaching effects of COVID-19 (Coronavirus) on Pemphigus Vulgaris Market, companies are on the lookout for new opportunities to sustain in the coming years. Gain new insights into the market and alternative solutions for keeping production steady in unforeseen circumstances.
Pemphigus Vulgaris Market Overview:
Pemphigus vulgaris, an autoimmune disease, is quite common in the US. This causes painful lesions on the mucous membranes. The disease affects neck, face, scalp, and back, sometimes it spreads even further to the armpits and the genitalia. The lesion can join up with each other and can make a much more severe attack on the face. This will make swallowing things difficult. The global Pemphigus Vulgaris Market is expected to reach a valuation of USD 677.99 million by 2027 at an 8% CAGR during the forecast period (2018-2027). Market Research Future (MRFR), in their recently revealed report, claims that its factors are going to play an assertive role for the furtherance of the pemphigus vulgaris market.
Factors like advancement in medicine is expected to take the market forward. Also, robust healthcare infrastructure is expected to boost the market in the coming years. Diagnostic procedures are also undergoing a sea-change, which can be of great importance for the market.
Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/sample_request/6870
Pemphigus Vulgaris Market Segmentation:
MRFR segmented the global pemphigus vulgaris market to have a closer peek at the market. This segmentation includes treatment, route of administration, and end-use.
Based on the treatment type, the pemphigus vulgaris market includes corticosteroids, biological therapies, immunosuppressants, and intravenous immunoglobulin (IVIG) therapy. The immunosuppressants has almost 31% share in the global pemphigus vulgaris market, and the corticosteroids segment is to follow with 28.6% share.
Based on the route of administration, the pemphigus vulgaris market includes intravenous, subcutaneous, and oral. The intravenous administration is the most-used process among various methods of drug administration. The segment had 40.6% of the global market share, in 2017.
By end-use, the pemphigus vulgaris market includes hospitals & clinics, specialty dermatology clinics, and research & academic laboratories. The hospitals and clinics segment had a valuation of USD 141 million in 2017 and is expected to showcase 8.2% CAGR during the review period. The specialty dermatology clinics segment has the potential to register 8.1% CAGR over the forecast period.
Pemphigus Vulgaris Market Regional Analysis:
Region-specific segmentation of the pemphigus vulgaris market, as conducted by MRFR, includes a detailed study of the Americas, Europe, Asia Pacific, and Rest-of-the-World (RoW).
The Americas market has the maximum market share. With 43.4% of the global pemphigus vulgaris market in 2017, the region is leading the market. Technological innovation and robust infrastructure are going to drive the regional market forward. The region is divided into North America and South America. North America is doing better with country-specific markets like the U.S., and Canada.
Europe is following the lead with 38.5% share. Presence of countries like France, the UK, Germany, and others are expected to take the regional market forward. These two regions are witnessing such a surge in the number of people affected with the disease due to the growing number of people of Mediterranean descent. The Americas has the potential to climb up to a valuation of USD 297.41 million by 2027 at a CAGR of 8.1% over the assessment period. The European pemphigus vulgaris market to surpass a valuation of USD 261.37 million by 2027.
Pemphigus Vulgaris Market Competitive Landscape:
Several players in the global pemphigus vulgaris market are showing keen interest in taking their prospect ahead by implementing strategic moves. MRFR, in their latest report on the market, profiled several companies like Biogen Inc. (U.S.), Almirall SA (Spain), F. Hoffman-La Roche (Switzerland), Argenx SE (Belgium), Syntimmune (India), Sanofi (France), Pfizer Inc. (U.S.), Janssen Global Services LLC (U.S.), Novartis AG (Switzerland), and Principia Biopharma (U.S.). The report tracks their recent moves to get a good grasp over the market trends.
Browse Complete Report with TOC at https://www.marketresearchfuture.com/reports/pemphigus-vulgaris-market-6870
In June 2019, the National Institute of Allergy and Infectious Diseases donated the Autoimmunity Center of Excellence at Penn an amount of USD 4.5 million to influence researches on autoimmune diseases. With the fund, researchers are planning to lead a trial testing for a technique named DSG3-CAART on pemphigus vulgaris. This is a part of their new immunotherapy plan.